Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Androgen | 15 | 2020 | 126 | 1.970 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2022 | 190 | 1.400 |
Why?
|
| Prostatic Neoplasms | 18 | 2020 | 935 | 1.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2012 | 269 | 1.080 |
Why?
|
| Androgens | 4 | 2020 | 89 | 0.870 |
Why?
|
| Cell Nucleus | 3 | 2020 | 366 | 0.850 |
Why?
|
| Transcription Factors | 4 | 2022 | 681 | 0.720 |
Why?
|
| Transcription, Genetic | 4 | 2020 | 578 | 0.670 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2020 | 187 | 0.670 |
Why?
|
| Cell Line, Tumor | 14 | 2020 | 2231 | 0.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2013 | 807 | 0.540 |
Why?
|
| Signal Transduction | 11 | 2020 | 1908 | 0.510 |
Why?
|
| Caspases | 3 | 2011 | 147 | 0.500 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 54 | 0.460 |
Why?
|
| Threonine | 1 | 2012 | 25 | 0.420 |
Why?
|
| Membrane Microdomains | 4 | 2007 | 47 | 0.410 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 219 | 0.400 |
Why?
|
| Phosphorylation | 5 | 2020 | 928 | 0.340 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2009 | 1 | 0.340 |
Why?
|
| Joint Instability | 1 | 2009 | 4 | 0.340 |
Why?
|
| Tendons | 1 | 2009 | 3 | 0.340 |
Why?
|
| Male | 20 | 2020 | 20025 | 0.310 |
Why?
|
| Prostate-Specific Antigen | 4 | 2013 | 118 | 0.280 |
Why?
|
| RNA Interference | 2 | 2020 | 243 | 0.260 |
Why?
|
| Humans | 24 | 2020 | 37093 | 0.250 |
Why?
|
| Transcriptional Activation | 2 | 2005 | 172 | 0.250 |
Why?
|
| Protein Kinases | 1 | 2005 | 100 | 0.250 |
Why?
|
| Response Elements | 1 | 2004 | 56 | 0.240 |
Why?
|
| Receptor, EphA3 | 1 | 2022 | 1 | 0.210 |
Why?
|
| Animals | 9 | 2017 | 15081 | 0.210 |
Why?
|
| Pyrimidines | 2 | 2013 | 118 | 0.200 |
Why?
|
| Mice | 5 | 2017 | 5913 | 0.200 |
Why?
|
| Receptors, Estrogen | 3 | 2013 | 156 | 0.200 |
Why?
|
| NF-kappa B | 1 | 2004 | 339 | 0.190 |
Why?
|
| COS Cells | 3 | 2011 | 69 | 0.190 |
Why?
|
| Protein Phosphatase 2 | 1 | 2020 | 22 | 0.180 |
Why?
|
| Databases, Genetic | 1 | 2020 | 93 | 0.180 |
Why?
|
| Mice, Nude | 3 | 2013 | 337 | 0.170 |
Why?
|
| Gene Expression | 2 | 2020 | 674 | 0.170 |
Why?
|
| Transfection | 6 | 2007 | 523 | 0.160 |
Why?
|
| Hydantoins | 1 | 2018 | 3 | 0.160 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 18 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 239 | 0.160 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 409 | 0.150 |
Why?
|
| Genistein | 1 | 2018 | 42 | 0.150 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 189 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2015 | 152 | 0.150 |
Why?
|
| Cytoplasm | 1 | 2017 | 143 | 0.150 |
Why?
|
| Drug Design | 1 | 2018 | 162 | 0.140 |
Why?
|
| Down-Regulation | 4 | 2009 | 435 | 0.140 |
Why?
|
| Prostate | 1 | 2017 | 154 | 0.140 |
Why?
|
| Cholesterol | 2 | 2007 | 205 | 0.130 |
Why?
|
| Histones | 2 | 2014 | 190 | 0.130 |
Why?
|
| Cell Membrane | 3 | 2007 | 381 | 0.130 |
Why?
|
| Genes, myc | 1 | 2015 | 29 | 0.130 |
Why?
|
| Lymphoma, B-Cell | 1 | 2015 | 23 | 0.130 |
Why?
|
| Computational Biology | 1 | 2017 | 293 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 803 | 0.130 |
Why?
|
| Methylation | 1 | 2014 | 113 | 0.120 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2013 | 4 | 0.120 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2013 | 5 | 0.120 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2013 | 5 | 0.120 |
Why?
|
| Hela Cells | 2 | 2012 | 366 | 0.110 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 15 | 0.110 |
Why?
|
| Cell Survival | 3 | 2018 | 864 | 0.110 |
Why?
|
| DNA-Binding Proteins | 2 | 2007 | 539 | 0.110 |
Why?
|
| Gene Silencing | 1 | 2014 | 151 | 0.110 |
Why?
|
| Apoptosis | 2 | 2013 | 1398 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2013 | 85 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 132 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2013 | 515 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1198 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 37 | 0.100 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 90 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 502 | 0.100 |
Why?
|
| Androstenols | 1 | 2011 | 2 | 0.100 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2011 | 10 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2012 | 77 | 0.100 |
Why?
|
| Morpholines | 1 | 2012 | 69 | 0.100 |
Why?
|
| Androstadienes | 1 | 2011 | 18 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 60 | 0.100 |
Why?
|
| Chromones | 1 | 2012 | 54 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2011 | 36 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2012 | 859 | 0.100 |
Why?
|
| Chromatin | 1 | 2011 | 169 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 433 | 0.090 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2009 | 2 | 0.090 |
Why?
|
| Patellar Ligament | 1 | 2009 | 1 | 0.080 |
Why?
|
| Radiography | 1 | 2009 | 72 | 0.080 |
Why?
|
| Range of Motion, Articular | 1 | 2009 | 31 | 0.080 |
Why?
|
| Binding Sites | 3 | 2009 | 651 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2007 | 408 | 0.080 |
Why?
|
| Protein Biosynthesis | 2 | 2009 | 133 | 0.080 |
Why?
|
| Myristic Acid | 1 | 2007 | 3 | 0.080 |
Why?
|
| Zinc Fingers | 1 | 2007 | 26 | 0.070 |
Why?
|
| Models, Biological | 2 | 2007 | 677 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 2005 | 444 | 0.070 |
Why?
|
| Hormones | 1 | 2006 | 55 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 168 | 0.070 |
Why?
|
| Plasmids | 1 | 2007 | 246 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2009 | 1207 | 0.070 |
Why?
|
| Zebrafish | 1 | 2007 | 128 | 0.070 |
Why?
|
| Cycloheximide | 1 | 2005 | 30 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2005 | 68 | 0.060 |
Why?
|
| Disease Progression | 1 | 2007 | 601 | 0.060 |
Why?
|
| Phenotype | 1 | 2007 | 689 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 98 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 307 | 0.060 |
Why?
|
| Transcription Factor RelA | 1 | 2004 | 40 | 0.060 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2004 | 62 | 0.060 |
Why?
|
| Cell Division | 2 | 2001 | 307 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2004 | 172 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2009 | 2026 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 113 | 0.050 |
Why?
|
| Metribolone | 1 | 2001 | 3 | 0.050 |
Why?
|
| Testosterone Congeners | 1 | 2001 | 3 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2001 | 212 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2018 | 326 | 0.050 |
Why?
|
| DNA Primers | 3 | 2006 | 286 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2000 | 387 | 0.040 |
Why?
|
| Cell Movement | 1 | 2001 | 571 | 0.040 |
Why?
|
| Base Sequence | 3 | 2006 | 997 | 0.040 |
Why?
|
| Cell Line | 2 | 2013 | 1354 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 409 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2018 | 492 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1039 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2015 | 80 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 57 | 0.030 |
Why?
|
| Adenine | 1 | 2013 | 44 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2013 | 28 | 0.030 |
Why?
|
| Piperidines | 1 | 2013 | 77 | 0.030 |
Why?
|
| Adult | 1 | 2009 | 11712 | 0.030 |
Why?
|
| Androstenes | 1 | 2011 | 2 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 132 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 83 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 2 | 2001 | 111 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2011 | 163 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2001 | 623 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 229 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 972 | 0.020 |
Why?
|
| Cyclodextrins | 1 | 2007 | 10 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 141 | 0.020 |
Why?
|
| Genes, rel | 1 | 2006 | 1 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2006 | 5 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 252 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2006 | 76 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 295 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 92 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2001 | 16 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2000 | 50 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 93 | 0.010 |
Why?
|
| Dimerization | 1 | 2000 | 112 | 0.010 |
Why?
|
| Exons | 1 | 2000 | 88 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 136 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 399 | 0.010 |
Why?
|
| Estrogens | 1 | 2001 | 202 | 0.010 |
Why?
|
| Ligands | 1 | 2000 | 349 | 0.010 |
Why?
|
| Estradiol | 1 | 2000 | 262 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 1180 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2000 | 1568 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 1015 | 0.010 |
Why?
|